Description
Description
This page contains brief details about the drug bosutinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Bosutinib is an anti-cancer medication that belongs to tyrosine kinase inhibitors. The drug was first approved in September 2012 for treating patients with chronic, accelerated, or blast-phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant or can no longer benefit from other medications for CML. Later on, FDA approved bosutinib for the treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in December 19, 2017.
Mechanism of Action of Bosutinib
The active role of bosutinib is to block the enzyme tyrosine kinase. Specifically, it blocks the action of certain enzymes found in white blood cells. The Bcr-Abl gene is an oncogene (cancer-causing gene) created from the fusion of the two genes; breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This fusion results in the formation of the Philadelphia chromosome. The gene expresses a particular enzyme that promotes the progression of CML. They are involved in stimulating the cells to divide uncontrollably. By blocking the enzyme, bosutinib helps to control cell division, thereby controlling the growth and spread of the leukemia cells in CML.
Uses of Bosutinib
It is used to treat three stages of chronic myelogenous leukemia (CML) called ‘chronic phase’, ‘accelerated phase’, and ‘blast phase’ in patients who have already been treated with one or more tyrosine kinase inhibitors (medicines for CML which work in a similar way to Bosutinib) and became intolerant (no longer being benefited) to it. It is also used to treat newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Bosutinib Dosage available
Bosutinib is available as oral tablets in 100 mg, 400 mg, and 500 mg. The drug will be prescribed by the healthcare professional. Your physician will decide on the dose and frequency based on the severity of the disease, weight, and height. For Newly-diagnosed chronic phase (Ph+) CML, 400 mg orally once daily with food will be prescribed initially. For managing Chronic, accelerated, or blast phase (Ph+) CML with resistance or intolerance to prior therapy, 500 mg orally once daily with food is given. The doctor may increase the dose up to 600 mg once a day or reduce it or interrupt treatment according to how the medicine works for you and based on the side effects.
